Tuesday, January 31, 2017

Roche sees profit growth won't outstrip sales in 2017

Reuters: Health News
ZURICH (Reuters) - Roche on Wednesday forecast profit growth would not outstrip sales in 2017, with the biggest maker of cancer drugs facing competition for its older blockbuster medicines for the first time as patents expire.
ZURICH (Reuters) - Swiss drugmaker Roche said on Wednesday it remains committed to its diabetes care business following a report that the company was considering options for the unit.
Health News Headlines - Yahoo News

File photo of Roche tablets positioned in front of a displayed Roche logoBy John Miller ZURICH (Reuters) - Roche on Wednesday forecast profit growth would not outstrip sales in 2017, with the biggest maker of cancer drugs facing competition for its older blockbuster medicines for the first time as patents expire. Core earnings per share this year are now targeted to grow broadly in line with a low- to mid-single-digit sales rise, the Swiss group said in a statement, down from 2016 when EPS grew faster than revenue. Core earnings per share in 2016 rose 5 percent to 14.53 Swiss francs, while sales grew 4 percent to 50.6 billion francs.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts